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Abstract
Aptamers, single-stranded oligonucleotides, are an important class of molecular targeting ligand.
Since their discovery, aptamers have been rapidly translated into clinical practice. They have been
approved as therapeutics and molecular diagnostics. Aptamers also possess several properties that
make them uniquely suited to molecular imaging. This review aims to provide an overview of
aptamers’ advantages as targeting ligands and their application in molecular imaging.
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Molecular imaging uses specific probes, rather than the nonspecific contrast agents used in
conventional imaging, to visualize a particular target or biologic process. These imaging
probes function either by targeting a physiologic process or by targeting cellular biomarkers.
The latter type of imaging probe requires biologic targeting ligands that can bind to cellular
biomarkers with high sensitivity, specificity, and affinity. Although the development of such
biologic targeting ligands has focused mainly on peptides and antibodies, aptamers are a
relatively new type of targeting ligand and hold several key advantages over their protein
counterparts. This article aims to review the advantages of aptamers as targeting ligands and
the current progress in using aptamers in molecular imaging.
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APTAMERS AS MOLECULAR TARGETING LIGANDS
Aptamers are single-stranded DNA or RNA oligonucleotides that are approximately 20–100
bases in length (1). These molecules can spontaneously fold into well-defined 3-dimensional
structures and bind to their target molecules with high affinity and specificity (Fig. 1).
Aptamers can be selected to recognize a wide range of molecules, including proteins,
phospholipids, sugars, and other nucleic acids. The selection method is called systemic
evolution of ligands by exponential enrichment (SELEX), which was first described in 1990
(2). In SELEX, a large library (>1010) of random sequences of nucleic acids is subjected to a
selection process against a particular target. The aptamers that can bind to the target
molecule more tightly are preferentially amplified by each round of selection. After rounds
of selection, the aptamer that binds the target molecule with the highest affinity and
specificity is isolated.
Although aptamers are similar to antibodies in their ability to recognize and bind to target
molecules, they hold several advantages over antibodies as targeting ligands (3). First,
aptamers fold into 3-dimensional structures spontaneously, making them more resistant than
antibodies to pH and temperature changes. Antibodies, in contrast, generally cannot regain
their original conformation once they have been denatured. Such high stability also allows
aptamers to be more easily modified through chemical means than are antibodies. Second,
unlike antibodies, which require in vitro or in vivo production, aptamers are synthesized
chemically. Chemical synthesis of a short nucleic acid strand is more reliable, and there is
much less variation between production batches. Furthermore, aptamers are more
economical to produce and the scale-up is easier for aptamers than for antibodies. Another
important advantage of aptamers is that the selection process is not dependent on the
immunogenicity or the toxicity of the target. Lastly, aptamers are much smaller than
antibodies. Their small size can improve tissue penetration and increase systemic clearance;
both are excellent properties for imaging probes.
Aptamers also have some disadvantages and challenges. As single-strand nucleic acids, they
are prone to degradation by nucleases. Therefore, aptamers require chemical modifications
to slow down the degradation process (3). Although their small size is an advantage, it can
also be a disadvantage because aptamers’ clearance may be too rapid. The fast clearance has
largely limited aptamers’ translation as therapeutic agents.
CLINICAL APPLICATIONS OF APTAMERS
Since their discovery, nucleic acid aptamers have been developed for various clinical
applications, including in vitro diagnostics, molecular imaging, biomarker discovery, and
therapeutics. Current in vitro diagnostics, such as enzyme-linked immunosorbent assays,
rely primarily on antibody technology. As mentioned above, aptamers are able to target
molecules that are difficult for antibody generation. For this reason and because of
aptamers’ lower production cost, there is growing interest in the development of aptamer-
based in vitro diagnostics. Indeed, aptamer diagnostics have been developed for the
detection of a wide range of molecules (4). The first successfully commercialized aptamer-
based diagnostic assay is one that detects mycotoxin in grains for agriculture applications
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(5). Aptamers have also been shown to enable large-scale proteomic studies, which can also
be used for the discovery of novel biomarkers (6). Another key focus in the clinical
translation of aptamers has been the development of aptamer-based therapeutics.
Therapeutic strategies generally involve binding of an aptamer directly to a therapeutic
target to modulate its downstream signaling or to deliver a therapeutic cargo. Because
aptamers undergo rapid systemic clearance, aptamer therapeutics are best suited to
applications in which systemic circulation is avoided (e.g., ocular delivery) or the disease
process is temporal, such as clotting and bleeding. Today, there is one Food and Drug
Administration–approved aptamer therapeutic, pegaptanib (Macugen; Valeant
Pharmaceuticals), with many more under clinical investigation (7). Pegaptanib is a pegylated
aptamer that targets vascular endothelial growth factor, which plays a critical role in
angiogenesis involved in age-related macular degeneration. Lastly, aptamers have also been
studied for applications in molecular imaging. These applications will be reviewed in detail
in the following sections.
OPTIC IMAGING WITH APTAMER-BASED PROBES
Optic imaging, which includes fluorescence and bioluminescence, is a key imaging modality
for visualization of molecular processes both on the cellular level and on the organismic
level in small animals. Optical molecular imaging is critical in understanding physiologic
and disease processes and can provide invaluable insight to disease treatment. Aptamers’
small size and ability to target a wide range of molecules make them excellent molecular
imaging probes for cellular imaging. Aptamer-based imaging probes can be formulated
either by directly linking them to fluorescent molecules or by conjugating aptamers to
nanoparticle-based optical probes (8). These aptamer-based molecular imaging probes have
been used to image biomarkers and cellular proteins such as integrins, prostate-specific
membrane antigen (PSMA), and nucleolin. Though similar to antibody-based probes, the
small size of aptamers makes them better suited to the imaging of intracellular proteins than
antibodies.
Aptamers have several unique properties, which have also enabled novel imaging
applications. Shi et al. used the conformation change associated with aptamer-target binding
to generate activatable aptamer probes (AAP) (9). In this study, the authors engineered an
AAP, sgc8 (41b, dissociation constant [Kd] = 0.8 nM), that binds to CCRF-CEM
lymphoblastic lymphoma cells. Sgc8 is made up of 3 components: an aptamer sequence that
binds to CCRF-CEM cells, a linker, and a short DNA sequence with both a fluorophore and
a quencher covalently attached at either terminus. When the aptamer is free, its
conformation keeps the fluorophore near the quencher, resulting in quenched fluorescence.
However, when the probe binds to a target, its conformation change separates the
fluorophore from the quencher, resulting in active fluorescence. The authors demonstrated
that AAPs can be used in in vivo molecular imaging in small animals.
Aptamers’ ability to target a wide range of biomarkers, including small molecules, has
allowed unique applications for aptamer molecular probes. For example, Wu et al.
developed aptamers that can bind to adenosine triphosphate, a small-molecule target with a
significant role in cellular functions and signaling (10). Moreover, they integrated the AAP
Wang and Farokhzad Page 3






















concept from above, enabling the imaging and detection of cellular adenosine triphosphate
changes in real time.
MR IMAGING
Although MR imaging is generally known as an anatomic imaging modality, it can be used
in molecular imaging with the proper imaging probes. Aptamers have been conjugated to
paramagnetic molecules, including gadolinium-containing compounds and
superparamagnetic iron oxide nanoparticles (SPIONs), for MR imaging–based molecular
imaging (7). Our group has conjugated the A10 aptamer (56b, Kd 5= 20.5 nM), targeted
against PSMA on prostate cancer cells, to SPIONs (11). We demonstrated that the A10–
SPION conjugate can target PSMA-expressing prostate cancer cells with high sensitivity
and specificity and can be used as an MR imaging agent. Moreover, using the ability of
aptamers to carry doxorubicin, a chemotherapeutic, we showed that we can also deliver
doxorubicin to prostate cancer in a targeted fashion. In another study, Yigit el al. conjugated
2 aptamers that can target thrombin to SPIONS (12). The 2 aptamers, Thrm-A and Thrm-B,
target the fibrinogen-recognition exosite and the heparin binding exosite of thrombin,
respectively. The investigators showed that aptamer-functionalized SPIONs can be used to
detect thrombin. As a method to improve specificity, the best MR signal is generated when
thrombin binds to both Thrm-A and Thrm-B SPION conjugates.
CT IMAGING
Aptamer-based molecular probes have also been used in CT imaging. Kim et al. conjugated
the A10 aptamer, targeted against PSMA, to gold nanoparticles (13). Gold nanoparticles,
because of their high atomic number, can act as CT imaging contrast agents. The
investigators showed that A10-targeted nanoparticles can bind to PSMA-expressing prostate
cancer cells with high sensitivity and specificity. More importantly, they showed that the
A10–gold nanoparticle conjugate can be used as a molecular probe for the detection of
PSMA-expressing cancer cells by CT imaging.
ULTRASOUND IMAGING
Ultrasound is one of the most commonly used clinical imaging modalities. One of its main
limitations is image resolution. To overcome this limitation, contrast agents, such as
microbubbles, have been developed (14). To enable molecular imaging, investigators have
conjugated aptamers to microbubbles to formulate molecular ultrasound probes (15).
Nakatsuka et al. engineered a novel aptamer–cross-linked microbubble as a molecular
ultrasound imaging agent (16). The microbubbles are designed to show ultrasound activation
only at levels of thrombin associated with clot formation. To accomplish this, the
microbubbles are coated with polymer-DNA strands and aptamers that can bind to thrombin.
The aptamers also contain sequences that can bind to the DNA in a polymer–DNA complex,
enabling cross-linking on the microbubble surface. However, the binding of thrombin to
aptamer will displace the aptamers from the polymer–DNA complex. The investigators
demonstrated that these microbubbles can act as a stimulus-responsive contrast agent and
generate ultrasound signal in response to only the levels of thrombin. Such an aptamer-based
ultrasound contrast agent can be useful for imaging thrombosis.
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NUCLEAR IMAGING WITH APTAMER-BASED PROBES
Nuclear imaging holds the highest potential for the clinical translation of aptamer-based
molecular imaging probes. The very first report of an aptamer-based imaging probe was a
radiolabeled (99mTc) aptamer targeted against human neutrophil elastase to identify sites of
inflammation (8). When compared with a radiolabeled IgG, the aptamer probe achieved a
higher target-to-background ratio (4-fold) than that of IgG (3-fold). This difference was
attributed to the more rapid clearance of unbound aptamer probes than IgG probes.
The study on radiolabeled TTA1 best demonstrated the potential of aptamers as nuclear
imaging probes (17). The investigators radiolabeled the aptamer TTA1 (38b, Kd = 5 nM)
with 99mTc. TTA1 is targeted against the extracellular matrix protein tenascin-C, which is
expressed during tissue remodeling processes including angiogenesis and tumor growth.
Tenascin-C is also known to be overexpressed by a wide range of tumors, including lung,
breast, and prostate. Radiolabeled TTA1 was evaluated in mouse xenograft models of brain
and breast cancer. The investigators showed that TTA1 has a rapid clearance profile, with a
blood half-life of 2 min. The aptamers penetrated tumors quickly, with 6% of injected dose
in tumor at 10 min. At 60 min after injection, there is still 3% of the injected dose in tumor.
The tumor-to-blood ratio was 50 within 3 h, highlighting its high potential for clinical
translation (Fig. 2). Despite these exciting data, TTA1 has not been translated clinically. One
main reason can be the unclear significance of tenascin in clinical oncology. Recently, Pieve
et al. has formulated 99mTc-labeled aptamer probes that are targeted against the MUC1
protein, a well-established biomarker for several tumors, including breast cancer (18).
Similar to previous studies, these aptamer probes have rapid clearance and can target
MUC1-expressing cells in vivo in a mouse xenograft model of cancer.
Radiolabeled aptamers have also been used in cellular imaging and biologic studies. Hwang
et al. conjugated the AS1411 aptamer, targeted against nucleolin, to a cobalt-ferrite
nanoparticle that is also coated with fluorescent rhodamine (19). The conjugate was then
labeled with 67Ga. The final probe can be detected by fluorescent imaging, MR imaging,
and nuclear imaging. They demonstrated that the AS1411–nanoparticle probe can bind to
nucleolin-expressing tumor cells with specificity in vitro and in vivo.
CONCLUSION AND FUTURE DIRECTIONS
Aptamers, a relatively new class of targeting ligand, have already made a significant impact
on clinical medicine. Current research and clinical translation efforts are focused on
developing aptamers as therapeutics and molecular diagnostics. These efforts have resulted
in one therapeutic that is Food and Drug Administration–approved, as well as several more
therapeutics and diagnostics under investigation. On the other hand, aptamers also possess
many unique properties that are well suited to molecular imaging. Because of these
properties, aptamers are studied in a wide range of applications in molecular imaging. There
continues to be high interest in developing aptamer-based probes in pre-clinical research.
These studies will improve the technology and identify the potential applications for
aptamers in molecular imaging. The successful clinical translation of aptamer-based
molecular imaging probes will also require the development of aptamers against biomarkers
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that have high clinical significance. In summary, aptamers are excellent molecular targeting
ligands, and they hold great promise in improving molecular imaging.
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Binding of 13C-RNA aptamer to G protein–coupled receptor kinase (GRK2). (Reprinted
with permission of (20).)
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Nuclear imaging with radiolabeled TTA1. Molecular probe is able to detect both U251
glioblastoma xenograft and MDA-MB-235 breast tumor xenograft.
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